Literature DB >> 32196594

OIP5-AS1 promotes the progression of gastric cancer cells via the miR-153-3p/ZBTB2 axis.

X-H Zhi1, K Jiang, Y-Y Ma, L-Q Zhou.   

Abstract

OBJECTIVE: Gastric cancer (GC) remains a serious disease to human health with high mortality worldwide. Evolving evidence implied that long non-coding RNA Opa interacting protein 5-antisense RNA1 (OIP5-AS1) went in for the pathological progress of GC. Nevertheless, the potential molecular mechanism of OIP5-AS1 needed to be further investigated.
MATERIALS AND METHODS: Levels of OIP5-AS1, microRNA (miR)-153-3p, and zinc finger and BTB domain containing 2 (ZBTB2) were assessed using quantitative real-time polymerase chain reaction (qRT-PCR) or Western blot assays. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) was implemented to detect cell proliferation in vitro. Cell apoptosis was evaluated by flow cytometry. Besides, transwell assay was conducted to examine cell migration and invasion in AGS and MKN45 cells. The interaction between miR-153-3p and OIP5-AS1 or ZBTB2 was validated utilizing dual-luciferase reporter assay. Lastly, the role of OIP5-AS1 in tumor growth was researched through adopting xenograft tumor model.
RESULTS: OIP5-AS1 and ZBTB2 were strongly higher in GC tissues than noncancerous samples. OIP5-AS1 silencing remarkably curbed cell proliferation, migration and invasion, and elevated cell apoptosis in both AGS and MKN45 cells. Functional analysis indicated that OIP5-AS1 regulated ZBTB2 expression via binding to miR-153-3p. Moreover, the role of miR-153-3p in cell growth and metastasis was abrogated by ZBTB2 overexpression. Above all, OIP5-AS1 could reduce the growth of xenograft tumor in vivo.
CONCLUSIONS: OIP5-AS1 exerted its role via miR-153-3p/ZBTB2 axis in the progression of GC cells. These findings might supply a biomarker for the diagnosis and therapy of GC clinically.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32196594     DOI: 10.26355/eurrev_202003_20510

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

Review 1.  The role of lncRNA OIP5-AS1 in cancer development and progression.

Authors:  Cheng Zheng; Man Chu; Qiuli Chen; Cheng Chen; Zhi-Wei Wang; Xiao Chen
Journal:  Apoptosis       Date:  2022-03-22       Impact factor: 4.677

2.  Investigation of circulating lncRNAs as potential biomarkers in chronic respiratory diseases.

Authors:  Zsófia Gál; András Gézsi; Ágnes F Semsei; Adrienne Nagy; Monika Sultész; Zsuzsanna Csoma; Lilla Tamási; Gabriella Gálffy; Csaba Szalai
Journal:  J Transl Med       Date:  2020-11-10       Impact factor: 5.531

3.  Hsa_circ_0008537 facilitates liver carcinogenesis by upregulating MCL1 and Snail1 expression via miR‑153‑3p.

Authors:  Ge Yang; Xianyong Li; Jingbo Liu; Shengjie Huang; Yaguang Weng; Jing Zhu; Daiqiong Lin; Ou Jiang
Journal:  Oncol Rep       Date:  2021-01-19       Impact factor: 3.906

Review 4.  Oxidative Stress and Inflammation in Cardiovascular Diseases and Cancer: Role of Non-coding RNAs.

Authors:  Pieterjan Ginckels; Paul Holvoet
Journal:  Yale J Biol Med       Date:  2022-03-31

5.  LncRNA OIP5-AS1 Knockdown Targets miR-183-5p/GLUL Axis and Inhibits Cell Proliferation, Migration and Metastasis in Nasopharyngeal Carcinoma.

Authors:  Shuo Li; Mingxing Tang; Nan Zen; Junyi Liang; Xiao Xing; Danglin Huang; Fei Liu; Xiaomeng Zhang
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 6.  A comprehensive review on miR-153: Mechanistic and controversial roles of miR-153 in tumorigenicity of cancer cells.

Authors:  Saghar Yousefnia
Journal:  Front Oncol       Date:  2022-09-09       Impact factor: 5.738

Review 7.  Long non-coding RNA OIP5-AS1 (Cyrano): A context-specific regulator of normal and disease processes.

Authors:  Serena Wooten; Keriayn N Smith
Journal:  Clin Transl Med       Date:  2022-01

8.  LncRNA OIP5-AS1 reduces renal epithelial cell apoptosis in cisplatin-induced AKI by regulating the miR-144-5p/PKM2 axis.

Authors:  Siyuan Chang; Mingyang Chang; Gang Liu; Daqian Xu; Haili Wang; Rongqing Sun; Min Feng
Journal:  Biomed J       Date:  2021-07-24       Impact factor: 7.892

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.